Shenzhen Neptunus Interlong Bio-technique Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shenzhen Neptunus Interlong Bio-technique.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	9.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Share Price Is Matching Sentiment Around Its Earnings

Sep 05

We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

Apr 19

These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely

Oct 03

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?

Mar 29

We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt

Sep 28

A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)

Aug 18

Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?

Jun 06

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Dec 15

Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.

Dec 29

Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly

Nov 24

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shenzhen Neptunus Interlong Bio-technique has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:8329 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	1,054	32	108	127	N/A
3/31/2024	1,045	27	N/A	N/A	N/A
12/31/2023	1,065	24	38	54	N/A
9/30/2023	1,120	64	N/A	N/A	N/A
6/30/2023	1,103	64	-77	-56	N/A
3/31/2023	1,071	60	N/A	N/A	N/A
12/31/2022	987	54	42	61	N/A
9/30/2022	931	47	N/A	N/A	N/A
6/30/2022	886	37	46	60	N/A
3/31/2022	835	31	N/A	N/A	N/A
12/31/2021	839	36	-85	-70	N/A
9/30/2021	868	33	N/A	N/A	N/A
6/30/2021	963	38	-72	-42	N/A
3/31/2021	1,056	43	N/A	N/A	N/A
12/31/2020	1,031	37	56	94	N/A
9/30/2020	1,077	52	N/A	N/A	N/A
6/30/2020	1,065	59	118	156	N/A
3/31/2020	1,059	57	N/A	N/A	N/A
12/31/2019	1,081	60	27	60	N/A
9/30/2019	1,006	56	N/A	N/A	N/A
6/30/2019	937	52	-5	24	N/A
3/31/2019	879	47	N/A	N/A	N/A
12/31/2018	867	48	-3	25	N/A
9/30/2018	862	43	N/A	N/A	N/A
6/30/2018	848	43	-6	26	N/A
3/31/2018	835	51	N/A	N/A	N/A
12/31/2017	790	50	N/A	56	N/A
9/30/2017	803	64	N/A	N/A	N/A
6/30/2017	772	64	N/A	77	N/A
3/31/2017	777	65	N/A	N/A	N/A
12/31/2016	759	63	N/A	83	N/A
9/30/2016	738	37	N/A	N/A	N/A
6/30/2016	726	29	N/A	43	N/A
3/31/2016	713	20	N/A	N/A	N/A
12/31/2015	721	21	N/A	62	N/A
9/30/2015	664	19	N/A	N/A	N/A
6/30/2015	662	23	N/A	60	N/A
3/31/2015	650	31	N/A	N/A	N/A
12/31/2014	648	33	N/A	39	N/A
9/30/2014	633	30	N/A	N/A	N/A
6/30/2014	630	27	N/A	60	N/A
3/31/2014	603	37	N/A	N/A	N/A
12/31/2013	612	36	N/A	29	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 8329's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 8329's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 8329's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8329's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 8329's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 8329's Return on Equity is forecast to be high in 3 years time

Shenzhen Neptunus Interlong Bio-technique Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Share Price Is Matching Sentiment Around Its Earnings

Second quarter 2024 earnings released: EPS: CN¥0.011 (vs CN¥0.008 in 2Q 2023)

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report First Half, 2024 Results on Aug 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.012 (vs CN¥0.01 in 1Q 2023)

Shenzhen Neptunus Interlong Bio-technique Company Limited, Annual General Meeting, Jun 21, 2024

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report Q1, 2024 Results on May 27, 2024

We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings

Full year 2023 earnings released: EPS: CN¥0.014 (vs CN¥0.032 in FY 2022)

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.009 (vs CN¥0.009 in 3Q 2022)

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report Q3, 2023 Results on Nov 07, 2023

These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely

Second quarter 2023 earnings released: EPS: CN¥0.008 (vs CN¥0.006 in 2Q 2022)

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report First Half, 2023 Results on Aug 11, 2023

Shenzhen Neptunus Interlong Bio-Technique Company Limited Announces Appointment of Executive Director and Retirement of Non-Executive Director

Shenzhen Neptunus Interlong Bio-technique Company Limited, Annual General Meeting, Jun 21, 2023

First quarter 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.006 in 1Q 2022)

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?

Full year 2022 earnings released: EPS: CN¥0.032 (vs CN¥0.021 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.003 in 3Q 2021)

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report Nine Months, 2022 Results on Nov 08, 2022

We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt

A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)

Second quarter 2022 earnings released

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report First Half, 2022 Results on Aug 12, 2022

Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?

Shenzhen Neptunus Interlong Bio-technique Company Limited, Annual General Meeting, Jun 24, 2022

First quarter 2022 earnings released

Shenzhen Neptunus Interlong Bio-Technique Company Limited Appoints Jin Rui as Non-Executive Director

Less than half of directors are independent

Full year 2021 earnings released

Shenzhen Neptunus Interlong Bio-technique Company Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?

Third quarter 2021 earnings released

Second quarter 2021 earnings released

First quarter 2021 earnings released

Full year 2020 earnings released

Shenzhen Neptunus Interlong Bio-Technique Company Limited Appoints Zhang Yi Fei as Non-Executive Director, Effective March 1, 2021

GM, Authorized Representative & Executive Director has left the company

Shenzhen Neptunus Interlong Bio-Technique Company Limited Announces Executive Changes

Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.

New 90-day low: HK$0.33

Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly

Third quarter 2020 earnings released: EPS CN¥0.006

New 90-day high: HK$0.39

New 90-day high - HK$0.38

New 90-day high - HK$0.34

Earnings released

New 90-day high - HK$0.24

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies